| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A803 | 10C12 Featured |
|
|
| A804 | Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) Featured |
|
|
| A805 | PF-03732010 Featured |
|
|
| A806 | DS-6000A Featured |
|
|
| A807 | HKT288 Featured |
|
|
| A808 | Actoxumab Featured | Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB. |
|
| A810 | Chaim Sheba Med. Cntr. patent anti-CEACAM1 Featured |
|
|
| A811 | Tusamitamab Featured | Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). |
|
| A812 | Labetuzumab Featured | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
|
| A813 | Tinurilimab Featured | Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. |
|
| A814 | NEO-201 Featured |
|
|
| A815 | Brown U. patent anti-CHI3L1 Featured |
|
|
| A816 | Academia Sinica patent anti-Clathrin Heavy Chain Featured |
|
|
| A817 | Zolbetuximab Featured | Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. |
|
| A818 | DS-9606A Featured | DS-9606A is a humanized antibody expressed in CHO cells, targeting CLDN6. DS-9606A features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for DS-9606A can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A819 | Anti-CLDN6 Reference Antibody (64A) Featured |
|
|
| A820 | Anti-CLDN6 Antibody (AB3-7) Featured |
|
|
| A821 | Anti-CLDN6 Reference Antibody (AE3-20) Featured |
|
|
| A822 | Anti-CLDN6 Reference Antibody (IM-302) Featured |
|
|
| A823 | Tepoditamab Featured | Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. |
|
| A824 | Scripps Korea patent anti-CLEC14A Featured |
|
|
| A825 | Litifilimab Featured | Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study. |
|
| A826 | LFB patent anti-BDCA-2 Featured |
|
|
| A827 | Baylor patent anti-Dectin-1 Featured |
|
|
| A828 | Sotevtamab Featured | Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research. |
|
| A829 | Empasiprubart Featured | Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models. |
|
| A830 | NGM-621 Featured |
|
|
| A831 | Crovalimab Featured | Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research. |
|
| A832 | Pozelimab Featured | Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases. |
|
| A833 | Ravulizumab Featured | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
|
